Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants

Status Recruiting

Clinical Trial Summary

This study has been designed to demonstrate that red blood cell from umbilical cord blood (UCB-RBC) is a safe and available product for extremely preterm infants (EPI) transfusion and that transfusion of UCB-RBC is non-less effective than RBC from adult donor for the treatment of anemia of prematurity in this group of patients.

Clinical Trial Description

Prematurity is an important maternal and child health problem due to its incidence and associated complications. Anaemia is a frequent problem in extremely preterm infants (EPI) whose treatment often requires red blood cell (RBC) transfusion. This product is currently obtained from adult blood (AB) donor. The incidence of some prematurity complications have been demonstrated to increase with AB-RBC tranfusions mainly because of the higher oxygen tissue release, such as retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and necrotizing enterocolitis (NEC). In addition, AB-RBC could contain small amounts of heavy metals that could be toxic for EPI. RBC from umbilical cord blood (UCB-RBC) might be a better alternative as it does not change the hemoglobin profile and consequently might decrease the oxygen toxicity. Several studies have evaluated the safety of UCB-RBC transfusions in preterm infants without finding a higher risk of complications compared with AB-RBC transfusions. A pilot study has been designed to evaluate the safety of UCB-RBC for transfusion in EPI and to determine the feasibility and efficacy of UCB-RBC for transfusion in this group of patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05612919
Study type	Interventional
Source	Hospital Clinic of Barcelona
Contact	Miguel María Alsina Casanova, MD
Phone	0034 93 227 56 00
Email	mmalsina@clinic.cat
Status	Recruiting
Phase	N/A
Start date	September 13, 2023
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03089047` - Rejuvenated RBC and VO2 Max in Healthy Subjects	Phase 4
Completed	`NCT03776266` - The Long-term Clinical Outcomes and Patterns of Transfusion in PCI Patients: Retrospective Cohort Study
Completed	`NCT01341002` - Red Blood Cells (RBC) Transfusion Related to Central Venous O2 Saturation (ScvO2) Measurement	N/A
Completed	`NCT00600704` - Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery	N/A
Completed	`NCT02604433` - An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia	Phase 3
Terminated	`NCT03092297` - Insufficient Cellular Oxygen in ICU Patients With Anaemia
Completed	`NCT03983694` - Cerebral Haemodynamic Changes by Red Blood Cell Transfusion in Neonates
Recruiting	`NCT05835882` - Blood Salvage From Liver Donors: a Feasibility Pilot Study	N/A
Completed	`NCT01541319` - Mechanism and Repository Study for the Red Cell Storage Duration Study	N/A
Completed	`NCT03788148` - Bare Metal Stents and Drug Eluting Stents in Patients Who Underwent Blood Transfusion
Completed	`NCT01274390` - Impact of Blood Storage Duration on Physiologic Measures	N/A
Completed	`NCT00991341` - Red Cell Storage Duration Study	Phase 3
Completed	`NCT01604083` - European Transfusion Practice and Outcome Study
Completed	`NCT02253654` - Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4